PDCD1 and head and neck squamous cell carcinoma: In recent years, immunotherapy involving checkpoint inhibitors blocking programmed cell death protein 1 (PD-1) or programmed death ligand-1 (PD-L1) has been approved for clinical use, with preliminary results showing that the strategy significantly improves the overall survival of recurrent or metastatic HNSCC patients.